CareDx, Inc. and the Board of Trustees of the Leland Stanford Junior University earlier this week filed a petition for certiorari with the U.S. Supreme Court asking the justices to review a 2022 decision holding certain claims of its patents directed to detection levels of donor cell-free DNA (cfDNA) in the blood of an organ transplant patient patent ineligible.
Recent Posts
- Clause 8: Ed Murgitroyd on Disrupting IP Services and Leading a Publicly Traded IP Law Firm
- USPTO Names New Advisory Board Members on Heels of PPAC Report Forecasting Downward Trend in Finances
- APPLE JAZZ Trademark Fight Continues at CAFC
- Straight to the Prompt: IP Lawyers Must Develop AI Skills NOW
- This Week in Washington IP: Evaluating the U.S.’s Role in IP Leadership, CHIPS Act Successes and Semiconductor Production, and the White House Policy on AI